171050-09-2

Upstream product

• 7440-02-0 nickel 
• 171050-08-1 N-[[2-cyano-4-t-butoxycarbonyl]phenyl]-L-aspartic acid β-methyl ester 
• 171050-07-0 t-butyl 4-fluoro-3-cyanobenzoate 
• 171050-06-9 3-cyano-4-fluorobenzoic acid 
• 179897-89-3 5-Bromo-2-fluoro-benzonitrile 
• 2177-62-0 β-methyl L-aspartate 

Downstream Products

• 171050-10-5 N-[[2-(N-methyl)aminomethyl-4-t-butoxycarbonyl]phenyl]-L-aspartic acid β-methyl ester 

Relevant academic research and scientific papers

Bicyclic fibrinogen antagonists

PCT No. PCT/US95/00248 Sec. 371 Date Jul. 3, 1996 Sec. 102(e) Date Jul. 3, 1996 PCT Filed Jan. 9, 1995 PCT Pub. No. WO96/18619 PCT Pub. Date Jul. 13, 1995Certain compounds within formula (I) are inhibitors of platelet aggregation: wherein A1 is NH or CH2;

An Alternate Enantiospecific Synthesis of Methyl (S)-7-tert-Butoxycarbonyl-2,3,4,5-Tetrahydro-4-Methyl-3-Oxo-1H-1,4-Benzodiazepine-2-Acetate

An alternate enantiospecific synthesis of methyl (S)-7-tert-butoxycarbonyl-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetate (5) is reported.The key step, which involves an intermolecular displacement of the activated aryl fluoride (9) by L-aspartic acid β-mehtyl ester, proceeds without racemization.